AZN.L - AstraZeneca PLC

LSE - LSE Delayed price. Currency in GBp
4,935.50
+10.50 (+0.21%)
As of 9:58AM GMT. Market open.
Stock chart is not supported by your current browser
Previous close4,925.00
Open4,911.00
Bid4,934.50 x 6100
Ask4,936.00 x 13000
Day's range4,903.50 - 4,945.00
52-week range4,136.50 - 5,520.00
Volume179,975
Avg. volume2,246,565
Market cap62.482B
Beta0.63
PE ratio (TTM)16.19
EPS (TTM)304.90
Earnings date2 Feb 2018
Forward dividend & yield2.79 (4.51%)
Ex-dividend date2017-08-10
1y target est69.25
  • AstraZeneca plc isn’t the only pharma stock I’d buy today
    Fool.co.uk2 days ago

    AstraZeneca plc isn’t the only pharma stock I’d buy today

    Royston Wild explains why AstraZeneca plc (LON: AZN) could make you a fortune.

  • 3 High-Yield Dividend Stocks to Buy in 2018
    Motley Fool3 days ago

    3 High-Yield Dividend Stocks to Buy in 2018

    These 3 Big Pharma stocks may be worth adding to your portfolio in 2018.

  • Reuters3 days ago

    Merck raises stakes in lung cancer as rivals close in

    Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer. Shares of Merck have fallen 10 percent since the drugmaker several weeks ago said it would make survival a main goal of a key lung cancer trial for immunotherapy Keytruda, extending the study by up to a year. In the meantime, Roche Holding AG has shaken up Wall Street expectations for the $15-billion (£11.3 billion) lung cancer market, showing its Tecentriq immunotherapy slows the spread of advanced lung cancer when combined with older treatments.

  • Why I’d buy FTSE 100 star Legal & General Group plc as profits set to hit record high
    Fool.co.uk7 days ago

    Why I’d buy FTSE 100 star Legal & General Group plc as profits set to hit record high

    Roland Head explains why Legal & General Group plc (LON:LGEN) is one of his top FTSE 100 (INDEXFTSE:UKX) picks.

  • Reuters7 days ago

    Companies prepare for disorderly Brexit as talks stall

    Big companies are stepping up their plans in case Britain crashes out of the European Union without a deal as Prime Minister Theresa May struggles to get talks back on track after a major setback. Britain is aiming to agree with the EU on Dec. 14 to move the Brexit talks on to the second phase. Senior executives in the financial services sector, which accounts for about 12 percent of the economy, told Reuters May's efforts to secure a transition deal had come too late and they had no choice but to start restructuring.

  • Reuters - UK Focus7 days ago

    Companies prepare for disorderly Brexit as talks stall

    LONDON, Dec (Shanghai: 600875.SS - news) 7 (Reuters) - Big companies are stepping up their plans in case Britain crashes out of the European Union without a deal as Prime Minister Theresa May struggles to get talks back on track after a major setback. Britain is aiming to agree with the EU on Dec. 14 to move the Brexit talks on to the second phase. This would focus on trade and a two-year transition deal to smooth the departure after March 2019.

  • Why Clovis' Good News In Ovarian Cancer Prodded These Rivals Down
    Investor's Business Daily8 days ago

    Why Clovis' Good News In Ovarian Cancer Prodded These Rivals Down

    Clovis rose Wednesday to the detriment of Tesaro and AstraZeneca after the FDA accepted its application for expanded use of its PARP inhibitor known as Rubraca.

  • GSK, other drugmakers bet on post-Brexit UK science
    Reuters8 days ago

    GSK, other drugmakers bet on post-Brexit UK science

    Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy plans after Brexit. The move is welcome news for Prime Minister Theresa May, who has struggled to win over large sections of industry as Britain prepares to leave the European Union. Thanks to the strength of UK universities and the presence of two major pharmaceuticals companies in GlaxoSmithKline and AstraZeneca, the drugs industry has been a bright spot in the British economy for many years.

  • Reuters - UK Focus8 days ago

    GSK, other drugmakers bet on post-Brexit UK science

    Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy ...

  • A Deadly Drug Cocktail Shines a Light on an AstraZeneca Blockbuster
    Bloomberg8 days ago

    A Deadly Drug Cocktail Shines a Light on an AstraZeneca Blockbuster

    Taking Seroquel with methadone can be fatal. Did the drugmaker’s warnings fall short?

  • Barrons.com8 days ago

    [$$] AstraZeneca Sells $10.7 Million in Albireo Stock

    AstraZeneca has halved its investment in Albireo Pharma. A subsidiary of AstraZeneca (ticker: AZN), AstraZeneca AB, sold 500,000 Albireo (ALBO) shares for $10.7 million, or $21.40 each on Dec. 1. AstraZeneca ...

  • FDA approves diabetes drug that also helps with weight loss
    Associated Press9 days ago

    FDA approves diabetes drug that also helps with weight loss

    TRENTON, N.J. (AP) — U.S. regulators on Tuesday approved a new diabetes drug that reduces blood sugar levels and also helps people lose significant weight.

  • Barrons.com9 days ago

    [$$] AstraZeneca Sells $6.6M in G1 Therapeutics Stock

    G1 Therapeutics, a clinical-stage oncology company, announced a collaboration with AstraZeneca Nov. 28. The pact will evaluate AstraZeneca’s (AZN) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) in combination with G1’s (GTHX) oral CDK4/6 inhibitor G1T38 for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). The press release didn’t mention that AstraZeneca, through its MedImmune Ventures subsidiary, is a significant shareholder in G1 nor that MedImmune Ventures has been selling G1 shares.

  • AstraZeneca's COPD Drug Succeeds in Label Expansion Study
    Zacks9 days ago

    AstraZeneca's COPD Drug Succeeds in Label Expansion Study

    AstraZeneca (AZN) releases positive top-line data from a phase IV study, evaluating label expansion of Tudorza for chronic obstructive pulmonary disease with cardiovascular risk factors.

  • Reuters - UK Focus10 days ago

    BUZZ-Circassia Pharmaceuticals: jumps on positive Tudorza data

    ** Circassia Pharmaceuticals up 2.2 pct -- having jumped as much as 12.7 pct in early trade to the top of FTSE Small Cap index ** Circassia and AstraZeneca say Tudorza meets primary endpoints and documented ...

  • 50,000 New Drug Tests Among Brexit Worries for Pharma Companies
    Bloomberg10 days ago

    50,000 New Drug Tests Among Brexit Worries for Pharma Companies

    Global drugmakers from Johnson & Johnson to AstraZeneca Plc warned that potential trade and regulatory hurdles may burden them with a host of additional costs after Britain leaves the European Union.

  • Market Realist13 days ago

    Gauging Novartis’s Valuation This November

    Novartis saw revenues of ~$12.4 billion and EPS of $1.29 for 3Q17, which represents a 2% YoY rise, compared with its revenues of ~$12.1 billion in 3Q16.

  • AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA
    Zacks15 days ago

    AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA

    AstraZeneca's (AZN) Marketing Authorisation Application for label expansion of Tagrisso has been accepted by the European Medicines Agency.

  • Market Realist15 days ago

    Nektar Therapeutics Raised Its Revenue Guidance for 2017

    After the collaboration with Eli Lilly for investigational drug NKTR-358, Nektar Therapeutics (NKTR) increased its 2017 revenue projections to $250 million–$255 million.

  • Reuters - UK Focus16 days ago

    Merck KGaA, Pfizer's immunotherapy fails in gastric cancer trial

    Germany's Merck KGaA has suffered a setback in the development of key cancer immunotherapy Bavencio, it having failed in a trial to prolong lives in gastric cancer patients when compared with standard ...

  • AstraZeneca Files for Label Expansion of Tagrisso in Japan
    Zacks16 days ago

    AstraZeneca Files for Label Expansion of Tagrisso in Japan

    AstraZeneca (AZN) files a regulatory application in Japan to expand the label of Tagrisso for first-line treatment of patients with non-small cell lung cancer.

  • Reuters - UK Focus17 days ago

    Britain's FTSE edges higher, pharmaceuticals lead gainers

    British shares edged higher on Monday, reversing early losses thanks to strong rises in pharmaceutical and financial stocks. At 0948 GMT, Britain's blue-chip FTSE 100 index was up 0.24 percent at 7,427.39. ...

  • AstraZeneca steps up China push with new drug joint venture
    Reuters17 days ago

    AstraZeneca steps up China push with new drug joint venture

    Drugmaker AstraZeneca plans to turbo-charge its already substantial Chinese business through a new drug development joint venture with a state-backed private equity fund. The stand-alone business, Dizal Pharmaceutical, will be owned equally with the Chinese Future Industry Investment Fund (FIIF), which is part-owned by the China State Development & Investment Corporation, the companies said on Monday. By getting into bed with a local player, AstraZeneca aims to ride a wave of regulatory reform in China's pharmaceuticals sector and get new drugs to market more quickly.

  • Reuters17 days ago

    AstraZeneca steps up China push with new drug joint venture

    Drugmaker AstraZeneca plans to turbo-charge its already substantial Chinese business through a new drug development joint venture with a state-backed private equity fund. The stand-alone business, Dizal Pharmaceutical, will be owned equally with the Chinese Future Industry Investment Fund (FIIF), which is part-owned by the China State Development & Investment Corporation, the companies said on Monday. By getting into bed with a local player, AstraZeneca aims to ride a wave of regulatory reform in China's pharmaceuticals sector and get new drugs to market more quickly.

  • Reuters - UK Focus17 days ago

    AstraZeneca steps up China push with new drug joint venture

    Drugmaker AstraZeneca plans to turbo-charge its already substantial Chinese business through a new drug development joint venture with a state-backed private equity fund. The stand-alone business, Dizal Pharmaceutical, will be owned equally with the Chinese Future Industry Investment Fund (FIIF), which is part-owned by the China State Development & Investment Corporation, the companies said on Monday.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes